Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ValiRx plc ( (GB:VAL) ) just unveiled an update.
ValiRx PLC has announced an extension to its Letter of Intent with TheoremRx, allowing exclusivity until 31 May 2025 for the proposed sub-license of VAL201. This extension follows TheoremRx’s developments regarding a transaction with a NASDAQ listed company, which ValiRx believes could positively impact the sub-license agreement. However, the agreement remains non-binding, with no guarantee of execution or revenue generation. The extension aims to facilitate TheoremRx’s completion of its M&A transaction, crucial for executing the sub-license. ValiRx remains supportive of TheoremRx and will continue to monitor progress.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, aiming to accelerate the translation of innovative science into impactful medicines to improve patient lives. The company provides the scientific, financial, and commercial framework for rapid translation of scientific research into clinical development, selecting and incubating promising novel drug candidates for optimized development from pre-clinical to clinic and investor-ready assets. ValiRx collaborates across diverse scientific, technical, and commercial domains for a streamlined and cost-effective drug development process and partners with investors for further clinical development and commercialization.
YTD Price Performance: -89.41%
Average Trading Volume: 2,365,028
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £827.2K
See more data about VAL stock on TipRanks’ Stock Analysis page.
